REVELATION BIOSCIENCES, INC. (REVB): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-3.1 2 revb-ex3_1.htm EX-3.1 EX-3.1 Exhibit 3.1 REVELATION BIOSCIENCES, INC. a Delaware corporation THIRD AMENDED AND RESTATED BYLAWS As Amended June 24, 2026 ARTICLE I: STOCKHOLDERS Section 1.1: Annual Meetings . If required by applicable law, an annual meeting of stockholders
How this was made
The 30-second read
Why it matters
This type of disclosure can move a small-cap biotech stock if it reveals leadership instability, material severance, or significant compensation/equity grants; however, the provided body excerpt does not include those specifics.
Market read
Governance and compensation updates are disclosed, but the excerpt lacks the concrete executive/compensation details needed for a high-conviction trading signal.
What to watch
Traders should verify the full 8-K exhibits for (1) which officers departed, (2) whether any were terminated for cause, (3) new executive appointment details, and (4) any equity/option or severance terms that could affect dilution or cash burn expectations.
Background
The filing is an SEC Form 8-K citing Item 5.02 (director/officer departures, elections, appointments, and compensatory arrangements) and Item 5.07 (submission of matters to a vote of security holders).
Ticker impact
Revelation Biosciences filed an 8-K for director/officer departures and elections plus compensatory arrangements, signaling governance and pay-plan changes.
Likely limited immediate price impact unless the missing 8-K exhibit details specific executive changes or material compensation terms.
The excerpt confirms the filing items (5.02/5.07) but does not include the specific names, roles, or compensation figures that would drive a more confident trading view.
Market effects
No clear sector read-through from the provided excerpt beyond routine corporate governance updates.
None indicated.
None indicated.
Counterpoint
Director/officer changes and compensation updates are often routine and may not reflect operational problems; without named departures or material terms, market reaction may be muted.
Key entities
- issuerREVELATION BIOSCIENCES, INC.
Subject of the SEC 8-K disclosing director/officer changes and compensatory arrangements.
